SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO Classification of tumours of the central nervous system. Lyon, France: IARC Press; 2007.
  • 2
    Aghi MK, Carter BS, Cosgrove GR, et al. Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery. 2009; 64: 56-60; discussion 60.
  • 3
    Nakasu S, Fukami T, Jito J, Nozaki K. Recurrence and regrowth of benign meningiomas. Brain Tumor Pathol. 2009; 26: 69-72.
  • 4
    Yang SY, Park CK, Park SH, Kim DG, Chung YS, Jung HW. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatry. 2008; 79: 574-580.
  • 5
    Flickinger JC, Kondziolka D, Maitz AH, Lunsford LD. Gamma knife radiosurgery of imaging-diagnosed intracranial meningioma. Int J Radiat Oncol Biol Phys. 2003; 56: 801-806.
  • 6
    Kondziolka D, Mathieu D, Lunsford LD, et al. Radiosurgery as definitive management of intracranial meningiomas. Neurosurgery. 2008; 62: 53-58; discussion 58-60.
  • 7
    Herscovici Z, Rappaport Z, Sulkes J, Danaila L, Rubin G. Natural history of conservatively treated meningiomas. Neurology. 2004; 63: 1133-1134.
  • 8
    Bindal R, Goodman JM, Kawasaki A, Purvin V, Kuzma B. The natural history of untreated skull base meningiomas. Surg Neurol. 2003; 59: 87-92; discussion 92.
  • 9
    Braunstein JB, Vick NA. Meningiomas: the decision not to operate. Neurology. 1997; 48: 1459-1462.
  • 10
    Olivero WC, Lister JR, Elwood PW. The natural history and growth rate of asymptomatic meningiomas: a review of 60 patients. J Neurosurg. 1995; 83: 222-224.
  • 11
    Nakamura M, Roser F, Michel J, Jacobs C, Samii M. The natural history of incidental meningiomas. Neurosurgery. 2003; 53: 62-70; discussion 70-61.
  • 12
    Sughrue ME, Sanai N, Shangari G, Parsa AT, Berger MS, McDermott MW. Outcome and survival following primary and repeat surgery for World Health Organization grade III meningiomas. J Neurosurg. 2010; 113: 202-209.
  • 13
    Durand A, Labrousse F, Jouvet A, et al. WHO grade II and III meningiomas: a study of prognostic factors. J Neurooncol. 2009; 95: 367-375.
  • 14
    Jaaskelainen J, Haltia M, Servo A. Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol. 1986; 25: 233-242.
  • 15
    Kasuya H, Kubo O, Tanaka M, Amano K, Kato K, Hori T. Clinical and radiological features related to the growth potential of meningioma. Neurosurg Rev. 2006; 29: 293-296; discussion 296-297.
  • 16
    Matsuno A, Fujimaki T, Sasaki T, et al. Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas. Acta Neuropathol. 1996; 91: 504-510.
  • 17
    McGovern SL, Aldape KD, Munsell MF, Mahajan A, Demonte F, Woo SY. A comparison of World Health Organization tumor grades at recurrence in patients with non-skull base and skull base meningiomas. J Neurosurg. 2010; 112: 925-933.
  • 18
    Nakasu S, Nakasu Y, Nakajima M, Matsuda M, Handa J. Preoperative identification of meningiomas that are highly likely to recur. J Neurosurg. 1999; 90: 455-462.
  • 19
    Pasquier D, Bijmolt S, Veninga T, et al. Atypical and malignant meningioma: outcome and prognostic factors in 119 irradiated patients. A multicenter, retrospective study of the Rare Cancer Network. Int J Radiat Oncol Biol Phys. 2008; 71: 1388-1393.
  • 20
    Sade B, Chahlavi A, Krishnaney A, Nagel S, Choi E, Lee JH. World Health Organization grades II and III meningiomas are rare in the cranial base and spine. Neurosurgery. 2007; 61: 1194-1198; discussion 1198.
  • 21
    Mahmood A, Caccamo DV, Tomecek FJ, Malik GM. Atypical and malignant meningiomas: a clinicopathological review. Neurosurgery. 1993; 33: 955-963.
  • 22
    Maier H, Ofner D, Hittmair A, Kitz K, Budka H. Classic, atypical, and anaplastic meningioma: 3 histopathological subtypes of clinical relevance. J Neurosurg. 1992; 77: 616-623.
  • 23
    Louis DN SB, Budka H, von Deimling A, Kepes JJ: Meningiomas. In: KleihuesP, CaveneeWK, eds. Pathology and Genetics. Tumors of the Nervous System. Lyon, France: IARC Press; 2000: 176-184.
  • 24
    Liu Y, Liu M, Li F, Wu C, Zhu S. Malignant meningiomas: a retrospective study of 22 cases. Bull Cancer. 2007; 94: E27-E31.
  • 25
    Lee JH, Sade B, Choi E, Golubic M, Prayson R. Meningothelioma as the predominant histological subtype of midline skull base and spinal meningioma. J Neurosurg. 2006; 105: 60-64.
  • 26
    Kepes JJ. Presidential address: the histopathology of meningiomas. A reflection of origins and expected behavior? J Neuropathol Exp Neurol. 1986; 45: 95-107.
  • 27
    Figarella-Branger D, Roche PH, Daniel L, Dufour H, Bianco N, Pellissier JF. Cell-adhesion molecules in human meningiomas: correlation with clinical and morphological data. Neuropathol Appl Neurobiol. 1997; 23: 113-122.
  • 28
    Wibom C, Moren L, Aarhus M, et al. Proteomic profiles differ between bone invasive and noninvasive benign meningiomas of fibrous and meningothelial subtype. J Neurooncol. 2009; 94: 321-331.
  • 29
    Engenhart-Cabillic R, Farhoud A, Sure U, et al. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment. Strahlenther Onkol. 2006; 182: 641-646.
  • 30
    Rosenberg LA, Prayson RA, Lee J, et al. Long-term experience with World Health Organization grade III (malignant) meningiomas at a single institution. Int J Radiat Oncol Biol Phys. 2009; 74: 427-432.
  • 31
    Sanai N, Sughrue ME, Shangari G, Chung K, Berger MS, McDermott MW. Risk profile associated with convexity meningioma resection in the modern neurosurgical era. J Neurosurg. 2010; 112: 913-919.
  • 32
    Rohringer M, Sutherland GR, Louw DF, Sima AA. Incidence and clinicopathological features of meningioma. J Neurosurg. 1989; 71( 5 pt 1): 665-672.
  • 33
    Korhonen K, Salminen T, Raitanen J, Auvinen A, Isola J, Haapasalo H. Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression. J Neurooncol. 2006; 80: 1-7.
  • 34
    Whittle IR, Foo MS, Besser M, Vanderfield GK. Progesterone and oestrogen receptors in meningiomas: biochemical and clinicopathological considerations. Aust N Z J Surg. 1984; 54: 325-330.
  • 35
    Wolfsberger S, Doostkam S, Boecher-Schwarz HG, et al. Progesterone-receptor index in meningiomas: correlation with clinico-pathological parameters and review of the literature. Neurosurg Rev. 2004; 27: 238-245.
  • 36
    Hsu DW, Efird JT, Hedley-Whyte ET. Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg. 1997; 86: 113-120.
  • 37
    Tabernero MD, Espinosa AB, Maillo A, et al. Patient gender is associated with distinct patterns of chromosomal abnormalities and sex chromosome linked gene-expression profiles in meningiomas. Oncologist. 2007; 12: 1225-1236.
  • 38
    Keller A, Ludwig N, Backes C, et al. Genome wide expression profiling identifies specific deregulated pathways in meningioma. Int J Cancer. 2009; 124: 346-351.
  • 39
    Watson MA, Gutmann DH, Peterson K, et al. Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays. Am J Pathol. 2002; 161: 665-672.
  • 40
    Smith JS, Lal A, Harmon-Smith M, Bollen AW, McDermott MW. Association between absence of epidermal growth factor receptor immunoreactivity and poor prognosis in patients with atypical meningioma. J Neurosurg. 2007; 106: 1034-1040.